{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:31Z","timestamp":1784998951867,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beckman Coulter, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03063-6","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:21:09Z","timestamp":1781007669000},"page":"1567-1575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Volume-adjusted p2PSA-derived indices for predicting prostate cancer: the PROPHET study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hasumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomo","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hakariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH et al (2018) Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362:k3519. https:\/\/doi.org\/10.1136\/bmj.k3519","journal-title":"BMJ"},{"key":"3063_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MOU.0b013e32835259aa","volume":"22","author":"L Klotz","year":"2012","unstructured":"Klotz L (2012) Cancer overdiagnosis and overtreatment. Curr Opin Urol 22:203\u2013209. https:\/\/doi.org\/10.1097\/MOU.0b013e32835259aa","journal-title":"Curr Opin Urol"},{"key":"3063_CR3","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","volume":"185","author":"WJ Catalona","year":"2011","unstructured":"Catalona WJ, Partin AW, Sanda MG et al (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0\u00a0ng\/ml prostate specific antigen range. J Urol 185:1650\u20131655. https:\/\/doi.org\/10.1016\/j.juro.2010.12.032","journal-title":"J Urol"},{"key":"3063_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","volume":"57","author":"FH Jansen","year":"2010","unstructured":"Jansen FH, van Schaik RH, Kurstjens J et al (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921\u2013927. https:\/\/doi.org\/10.1016\/j.eururo.2010.02.003","journal-title":"Eur Urol"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/JU.0000000000000495","volume":"203","author":"K Ito","year":"2020","unstructured":"Ito K, Yokomizo A, Tokunaga S et al (2020) Diagnostic impacts of clinical laboratory based p2PSA indexes on any grade, Gleason grade group 2 or greater, or 3 or greater prostate cancer and prostate specific antigen below 10\u00a0ng\/ml. J Urol 203:83\u201391. https:\/\/doi.org\/10.1097\/JU.0000000000000495","journal-title":"J Urol"},{"key":"3063_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1159\/000356240","volume":"89","author":"E Kikuchi","year":"2000","unstructured":"Kikuchi E, Nakashima J, Ishibashi M et al (2000) Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer 89:842\u2013849. https:\/\/doi.org\/10.1159\/000356240","journal-title":"Cancer"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"3063_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1148\/radiology.201.3.8939225","volume":"201","author":"Y Jiang","year":"1996","unstructured":"Jiang Y, Metz CE, Nishikawa RM (1996) A receiver operating characteristic partial area index for highly sensitive diagnostic tests. Radiology 201:745\u2013750. https:\/\/doi.org\/10.1148\/radiology.201.3.8939225","journal-title":"Radiology"},{"key":"3063_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","volume":"21","author":"SP Balk","year":"2003","unstructured":"Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21:383\u2013391. https:\/\/doi.org\/10.1200\/JCO.2003.02.083","journal-title":"J Clin Oncol"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.urology.2019.03.018","volume":"129","author":"C Lopes Vendrami","year":"2019","unstructured":"Lopes Vendrami C, McCarthy RJ, Chatterjee A et al (2019) The utility of prostate specific antigen density, prostate health index, and prostate health index density in predicting positive prostate biopsy outcome is dependent on the prostate biopsy methods. Urology 129:153\u2013159. https:\/\/doi.org\/10.1016\/j.urology.2019.03.018","journal-title":"Urology"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bju.13762","volume":"120","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Druskin SC, Andreas D et al (2017) Prostate health index density improves detection of clinically significant prostate cancer. BJU Int 120:793\u2013798. https:\/\/doi.org\/10.1111\/bju.13762","journal-title":"BJU Int"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00345-020-03585-2","volume":"39","author":"C Stephan","year":"2021","unstructured":"Stephan C, Jung K, Lein M et al (2021) PHI density prospectively improves prostate cancer detection. World J Urol 39:3273\u20133279. https:\/\/doi.org\/10.1007\/s00345-020-03585-2","journal-title":"World J Urol"},{"key":"3063_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cca.2021.06.006","volume":"520","author":"MM Garrido","year":"2021","unstructured":"Garrido MM, Ribeiro RM, Pinheiro LC et al (2021) The prostate health index (PHI) density: are there advantages over PHI or over the prostate-specific antigen density? Clin Chim Acta 520:133\u2013138. https:\/\/doi.org\/10.1016\/j.cca.2021.06.006","journal-title":"Clin Chim Acta"},{"key":"3063_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071912","volume":"11","author":"Y Boo","year":"2023","unstructured":"Boo Y, Chung JH, Kang M et al (2023) Comparison of prostate-specific antigen and its density and prostate health index and its density for detection of prostate cancer. Biomedicines 11:1912. https:\/\/doi.org\/10.3390\/biomedicines11071912","journal-title":"Biomedicines"},{"key":"3063_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00345-012-0927-9","volume":"31","author":"K Ito","year":"2013","unstructured":"Ito K, Miyakubo M, Sekine Y et al (2013) Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0\u00a0ng\/mL range. World J Urol 31:305\u2013311. https:\/\/doi.org\/10.1007\/s00345-012-0927-9","journal-title":"World J Urol"},{"key":"3063_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231201122","volume":"17","author":"YH Qian","year":"2023","unstructured":"Qian YH, Shi YT, Sheng XJ et al (2023) Evaluating the role of morphological parameters in the prostate transition zone in PHI-based predictive models for detecting gray zone prostate cancer. Clin Med Insights Oncol 17:11795549231201122. https:\/\/doi.org\/10.1177\/11795549231201122","journal-title":"Clin Med Insights Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03063-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:56Z","timestamp":1784997356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03063-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kazuhiro Suzuki received lecture fee from Beckman Coulter, Inc..","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PROPHET study was approved by the Certified Review Board, and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol number. UMIN000016934). All participants provided written informed consent.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}